10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

Cited by (487)

Items 201–300 of 487

1. Prediction and early detection of cardiovascular disease in South Asians with diabetes mellitus
   Gagandeep Singh Wander, Manish Bansal, Ravi Ratan Kasliwal · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
2. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies
   Yuwen Cai, Weinan Shi, Gaosi Xu · 2020 · Expert Opinion on Drug Safety
3. Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes
   Nuntakorn Thongtang, Natthakan Tangkittikasem, Kittichai Samaithongcharoen, Jirasak Piyapromdee, Varalak Srinonprasert, Sutin Sriussadaporn · 2020 · Vascular Health and Risk Management
4. Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice
   Bruce A. Warden, Jonathan Q. Purnell, Paul Barton Duell, Courtney Craigan, Diane Osborn, Emily Cabot, Sergio Fazio · 2021 · American Journal of Preventive Cardiology
5. Biomarkers of fatty acid intake are independently associated with preclinical atherosclerosis in individuals with type 1 diabetes
   Alex Mesa, Montserrat Cofán, Enric Esmatjes, Verónica Perea, Laura Boswell, Marga Giménez, Aleix Sala‐Vila, Irene Vinagre, Clara Viñals, Gemma Chiva‐Blanch et al. · 2021 · European Journal of Nutrition
6. Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project
   Nan Ye, Lijiao Yang, Guoqin Wang, Weijing Bian, Fengbo Xu, Changsheng Ma, Dong Hui Zhao, Jing Liu, Yongchen Hao, Jun Liu et al. · 2020 · BMC Cardiovascular Disorders
7. Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists
   Emily J. Cox, Radica Z. Alicic, Joshua J. Neumiller, Katherine R Tuttle · 2020 · US Endocrinology
8. Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study
   Sangmo Hong, Jung Hwan Park, Kyungdo Han, Chang Beom Lee, Dong Sun Kim, Sung Hoon Yu · 2021 · Journal of the American Heart Association
9. The Theory of Hyperlipidemic Memory of Type 1 Diabetes
   Benjamin Udoka Nwosu · 2022 · Frontiers in Endocrinology
10. The diabetes cardiovascular outcomes trials and racial and ethnic minority enrollment: impact, barriers, and potential solutions
    Matthew R. Sinclair, Mariam M Ardehali, Clarissa Jonas Diamantidis, Leonor Corsino · 2024 · Frontiers in Public Health
11. Calidad de la atención en diabetes tipo 2, avances y retos de 2012 a 2018-19 para el sistema de salud de México
    Sergio Flores‐Hernández, Omar Acosta-Ruíz, María Isidra Hernández-Serrato, Sheila Delgado-Rodríguez, Hortensia Reyes‐Morales · 2020 · Salud Pública de México
12. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis
    Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri · 2021 · The American Journal of Medicine
13. Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus
    Qian Shi, Yilu Lin, Vivian Andrew Fonseca, Lizheng Shi · 2021 · BMJ Open Diabetes Research & Care
14. The Transcultural Diabetes Nutrition Algorithm: A Middle Eastern Version
    Osama Hamdy, Saud Al Sifri, Mohamed M. Hassanein, Mohammed A. Al Dawish, Raed Aldahash, Fatheya Alawadi, Nadim S. Jarrah, Hajar Ahmad Ballout, Refaat A. F. Hegazi, Ahmed Amin et al. · 2022 · Frontiers in Nutrition
15. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects
    Jiangli Jin, Gang Cui, Na Mi, Wei Wu, Xin Zhang, Chunyan Xiao, Jing Wang, Xueying Qiu, Mai Han, Ziyan Li et al. · 2023 · European Journal of Pharmaceutical Sciences
16. Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
    Jennifer D. Goldman · 2020 · Journal of Clinical Pharmacy and Therapeutics
17. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
    Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula Α. Paschou, Evangelos K. Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis, Dimitrios M. Tousoulis · 2020 · Current Pharmaceutical Design
18. Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options
    Sanjot S. Sunner, Robert C. Welsh, Kevin R. Bainey · 2021 · CJC Open
19. Rationale and design of the Brazilian diabetes study: a prospective cohort of type 2 diabetes
    Joaquim Barreto, Vaneza Lira Waldow Wolf, Isabella Bonilha, Beatriz Luchiari, Marcus Fernando Da Gama Lima, Alessandra Oliveira, Sofia Helena Vitte, Gabriela Stefany Lopes Machado, Jessica S. Cunha, Cynthia Moura Borges et al. · 2022 · Current Medical Research and Opinion
20. Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong Soo, Byung‐Wan Lee · 2022 · Endocrinology and Metabolism
21. Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
    Leili Gao, Zhifeng Cheng, Benli Su, Xiuhai Su, Weihong Song, Yushan Guo, Lin Liao, Xiaowen Chen, Jiarui Li, Xingrong Tan et al. · 2022 · Diabetes Obesity and Metabolism
22. Connections between Diabetes Mellitus and Metabolic Syndrome and the Outcome of Cardiac Dysfunctions Diagnosed during the Recovery from COVID-19 in Patients without a Previous History of Cardiovascular Diseases
    Cristina Tudoran, Renata Bende, Felix Bende, Cătălina Giurgi-Oncu, Alexandra Enache, Raluca Dumache, Mariana Tudoran · 2023 · Biology
23. Expert opinion on the preoperative medical optimization of adults with diabetes undergoing metabolic surgery
    Saptarshi Bhattacharya, Sanjay Kalra, Nitin Kapoor, Rajiv Singla, Deep Dutta, Sameer Aggarwal, Deepak Khandelwal, Vineet Surana, Atul Dhingra, Viny Kantroo et al. · 2021 · World Journal of Diabetes
24. Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li · 2023 · Journal of Health Population and Nutrition
25. Glucose‐lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology
    Tianpei Hong, Qing Su, Xiaoying Li, Zhongyan Shan, Li Chen, Yongde Peng, Liming Chen, Li Yan, Yuqian Bao, Zhaohui Lyu et al. · 2020 · Diabetes/Metabolism Research and Reviews
26. Statin use for primary prevention in patients with type 2 diabetes: Can it benefit all ages? - A nationwide propensity-matched cohort study.
    Eun Jun Ji, In-Kyung Jeong, Kyu Jeung Ahn, H. Chung, Y. Hwang · 2021 · Diabetes Research and Clinical Practice
27. Partial Clinical Remission of Type 1 Diabetes: The Need for an Integrated Functional Definition Based on Insulin-Dose Adjusted A1c and Insulin Sensitivity Score
    Benjamin Udoka Nwosu · 2022 · Frontiers in Endocrinology
28. Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study
    Thanapat Puangpet, Tanyaporn Pongkunakorn, Nahathai Chulkarat, Chutikan Bunlangjit, Apinya Surawit, Bonggochpass Pinsawas, Pichanun Mongkolsucharitkul, Korapat Mayurasakorn · 2022 · BMC Family Practice
29. An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
    Namrata Dagli, Santosh Kumar, Rahnuma Ahmad, Mahendra Narwaria, Mainul Haque · 2023 · Cureus
30. Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population
    Shuping Ruan, Xiaoqing Yuan, Juan Liu, Qing Zhang, Xinhua Ye · 2024 · Diabetes Metabolic Syndrome and Obesity
31. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects
    Gang Mai, Lianlian Fan, Mu-Peng Li, Peiwen Zhang, Chunyan Gan, Qian Huang, Jianzhong Shentu · 2021 · Frontiers in Pharmacology
32. The clinical characteristics of Chinese elderly patients with different durations of type 2 diabetes mellitus
    Yun Yu, Kaipeng Xie, Qinglin Lou, Hui Xia, Dan Wu, Lingli Dai, Cuining Hu, Shan Shan, Kunlin Wang, Wei Tang · 2022 · Frontiers in Endocrinology
33. Risk factors of previously undiagnosed and known untreated hypertension among patients with Type-2 diabetes mellitus
    Muhammad Adnan, Wasif Noor, Mirza Muhammad Ayub Baig · 2023 · Pakistan Journal of Medical Sciences
34. Primary Care Physicians’ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey
    Jay H. Shubrook, Jonathan Pak, GEORGE E. DAILEY · 2020 · Advances in Therapy
35. Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study
    Kevin Kris Warnakula Olesen, Morten Madsen, Christine Gyldenkerne, Pernille Gro Thrane, Troels Thim, Lisette Okkels Jensen, Hans Erik Bøtker, Henrik Toft Sørensen, Michael Mæng · 2021 · Cardiovascular Diabetology
36. The added value of electrocardiogram abnormalities in predicting incident cardiovascular disease risk for people with Type 2 diabetes: the Hoorn Diabetes Care System cohort
    Peter P. Harms, Reinier A.R. Herings, Sharon Remmelzwaal, Femke Rutters, Joline W. J. Beulens, Giel Nijpels, Petra J. M. Elders, Marieke Tabo Blom · 2025 · European Journal of Preventive Cardiology
37. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
    Manan Pareek, Richard Preston Mason, Deepak L. Bhatt · 2021 · Expert Opinion on Drug Safety
38. Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
    Joaquim Barreto, Beatriz Luchiari, Vaneza Lira Waldow Wolf, Isabella Bonilha, Ticiane Gonçalez Bovi, Barbara Assato, Ikaro Soares Santos Breder, Sheila T. Kimura-Medorima, Daniel Munhoz, Thiago Quinaglia et al. · 2022 · Diagnostics
39. Neuropathy scale score as an independent risk factor for myocardial infarction in patients with type 2 diabetes
    Lian Y. Wang, Simin Guo, Weimin Wang, Biyun Xu, Wei Chen, Yali Jing, Jiewen Jin, Chenxi Li, Yihua Zhou, Dalong Zhu · 2022 · Diabetes/Metabolism Research and Reviews
40. Five-year LDL-cholesterol trend and its predictors among type 2 diabetes patients in an upper-middle-income country: a retrospective open cohort study
    Kim Sui Wan, Noran Naqiah Hairi, Feisul Idzwan Mustapha, Mastura Ismail, Muhammad Fadhli Mohd Yusoff, Foong Ming Moy · 2022 · PeerJ
41. Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs
    Melissa Ribeiro-Silva, José Oliveira‐Pinto, Armando Mansilha · 2020 · International Angiology
42. Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society
    Raffaele Napoli, Gloria Formoso, Salvatore Piro, Giovanni Targher, Agostino Consoli, Francesco Purrello · 2020 · Nutrition Metabolism and Cardiovascular Diseases
43. Impact of national valsartan recalls on Veterans’ outcomes
    Paige L. Morizio, Sara R. Britnell, Andreina A. Ottman · 2021 · Therapeutic Advances in Drug Safety
44. Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives
    Martina Ambrož, Sieta T. de Vries, Klaas Hoogenberg, Petra Denig · 2021 · Frontiers in Pharmacology
45. Statins effect on insulin resistance after a meal and exercise in hypercholesterolemic pre‐diabetic individuals
    Laura Álvarez-Jiménez, Felix Morales‐Palomo, Alfonso Moreno‐Cabañas, JUAN FERNANDO ORTEGA, Ricardo Mora‐Rodríguez · 2022 · Scandinavian Journal of Medicine and Science in Sports
46. Low-Dose Aspirin Use Among African American Older Adults
    Mohsen Bazargan, Cheryl Wisseh, Edward K. Adinkrah, Shanika Boyce, Ebony King, Shervin Assari · 2021 · The Journal of the American Board of Family Medicine
47. Modification of the Association Between Severe Hypoglycemia and Ischemic Heart Disease by Surrogates of Vascular Damage Severity in Type 1 Diabetes During ∼30 Years of Follow-up in the DCCT/EDIC Study
    Elke R. Fährmann, LAURA J. ADKINS, Henry Keane Driscoll · 2021 · Diabetes Care
48. Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
    Rui Song, Hang Qian, Yunlian Wang, Qingmei Li, Dongfeng Li, Jishun Chen, Jingning Yang, Jixin Zhong, Handong Yang, Xinwen Min et al. · 2022 · Journal of Diabetes Research
49. Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
    Ana Lucrecia Marcano, Montserrat Gracida, Gerard Roura, Josep Gómez Lara, Rafael Romaguera, Luís Teruel, Lara Fuentes, Guillem Muntané‐Carol, Oona Meroño, Silvia Gabriela Sosa et al. · 2022 · Frontiers in Cardiovascular Medicine
50. Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application
    David Chen, Maya L. Petersen, Helene C. W. Rytgaard, Randi Grøn, Theis Lange, Søren Rasmussen, Richard E. Pratley, Steven P. Marso, Kajsa Kvist, John B. Buse et al. · 2023 · Statistics in Biopharmaceutical Research
51. Effect modification of the association between temperature variability and hospitalization for cardiovascular disease by comorbid diabetes mellitus: A nationwide time-stratified case-crossover analysis
    Akira Okada, Hayato Yamana, Rui Pan, Satoko Yamaguchi, Ryosuke Kumazawa, Hiroki Matsui, Kiyohide Fushimi, Yasushi Honda, Masaomi Nangaku, Toshimasa Yamauchi et al. · 2023 · Diabetes Research and Clinical Practice
52. The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)—Rationale and Meta-Analysis of Observational Studies
    Laura Rehak, Laura Giurato, Matteo Monami, Marco Meloni, Alessia Scatena, Andrea Panunzi, Giada Maria Manti, Carlo Maria Ferdinando Caravaggi, Luigi Uccioli · 2024 · Journal of Clinical Medicine
53. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial
    Magnus Olof Wijkman, Brian Lee Claggett, Rafael Díaz, Hertzel C. Gerstein, Lars Køber, Eldrin Foster Lewis, Aldo Pietro Maggioni, Emil Wolsk, David A. Aguilar, Rhonda Bentley–Lewis et al. · 2020 · Cardiovascular Diabetology
54. Triglycerides
    Najdat Bazarbashi, Michael J. Miller · 2022 · Medical Clinics of North America
55. The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression
    Yanfen Liu, Dongying Nie, Xueyong Lou · 2024 · DNA and Cell Biology
56. Diabetes consultation versus diabetes education in patients with poor glycaemic control: A telemedicine intervention study
    Ebenezer A. Nyenwe, Sydney Ashby, Jamie Tidwell · 2020 · Journal of Telemedicine and Telecare
57. A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus
    Neha Jadeja Pagidipati, PRAKASH C. DEEDWANIA · 2021 · The American Journal of Medicine
58. Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016
    Esben Skov Jensen, Kevin Kris Warnakula Olesen, Christine Gyldenkerne, Pernille Gro Thrane, Lisette Okkels Jensen, Bent Raungaard, Per Løgstrup Poulsen, Reimar Wernich Thomsen, Michael Mæng · 2021 · BMC Cardiovascular Disorders
59. Contraception use and knowledge related to pregnancy in diabetic women
    Louise Feutry, Coralie Barbe, Aurélie Marquet-Dupont, A. Fèvre, Céline Lukas-Croisier, Géraldine Vitellius, Brigitte Delemer, Sara Barraud · 2022 · Annales d Endocrinologie
60. Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
    Francesco Zaccardi, David E. Kloecker, Kamlesh K. Khunti, Melanie Jane Davies · 2022 · Diabetes Obesity and Metabolism
61. Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil
    Guilherme Silva Julian, Daniel Campos, Julie Broe Honoré, F.S. Tobaruella, Jung Hyun Yoon, Nino Hallén · 2020 · Journal of Medical Economics
62. Medical assistant health coaching (“MAC”) for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol
    Addie L. Fortmann, Athena Philis‐Tsimikas, Johanna A. Euyoque, Taylor L. Clark, Daniela G. Vital, Haley Sandoval, Julia Isabela Bravin, Kimberly L. Savin, Jennifer Anne Meri Jones, Scott C. Roesch et al. · 2020 · Contemporary Clinical Trials
63. Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study
    Febriana M Puspita, Em Yunir, Putri Syahida Agustina, Rani Sauriasari · 2021 · Diabetes Metabolic Syndrome and Obesity
64. Low grade intravascular hemolysis associates with peripheral nerve injury in type 2 diabetes
    Sylvain Le Jeune, Sihem Sadoudi, Dominique Charue, Salwa Abid, Jean‐Michel Guigner, Dominique Helley, H. Bihan, Camille Baudry, Hélène Lelong, Tristan Mirault et al. · 2022 · PLoS ONE
65. Relationship of Clinician Care Team Composition and Diabetes Quality Outcomes
    Benjamin D. Meyerink, Michelle A. Lampman, Susan B. Laabs, Randy M. Foss, Gregory M. Garrison, Kurt B. Angstman, Gerald J. Sobolik, Michael P. Halasy, Kristin J. Fischer, Steven Rosas et al. · 2020 · Population Health Management
66. Relationship Between Long-Term Objectively Measured Physical Activity and Glycemic Control in Type 2 Diabetes Mellitus Patients: A Prospective Cohort Study
    Masuda, Hiroaki, Ishiyama, Daisuke, Yamada, Minoru, Iwashima, Fumiko, Kimura, Yosuke, Otobe, Yuhei, Tani, Naoki, Suzuki, Mizue, Nakajima, Hideki · 2021 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
67. Cardiovascular disease risk evaluation impact in patients with rheumatoid arthritis
    Avi G. Aronov, Yoo Jin Kim, Nadera Sweiss, Noreen T. Nazir · 2022 · American Journal of Preventive Cardiology
68. Sleeve gastrectomy and one-year outcomes: Impact on cardiovascular, renal and metabolic parameters
    Maria Irene Bellini, Lidia Castagneto‐Gissey, Denise V. Nemeth, Vito D’Andrea, Giulio Illuminati, Serena Marchitelli, Silvia Lai, Giovanni Casella · 2024 · Surgery Open Science
69. Effects of antidiabetic drugs that cause glucose excretion directly from the body on mortality
    Hideya Shintani, Tomoya Shintani · 2020 · Medicine in Drug Discovery
70. Evolving Concepts of Type 2 Diabetes Management
    Layla A. Abushamat, Jane E.B. Reusch · 2021 · Medical Clinics of North America
71. Association of Pulmonary Function Decline over Time with Longitudinal Change of Glycated Hemoglobin in Participants without Diabetes Mellitus
    Wen-Hsien Lee, Da‐Wei Wu, Ying‐Chih Chen, Yi‐Hsueh Liu, Wei-Sheng Liao, Szu‐Chia Chen, Chih‐Hsing Hung, Chao‐Hung Kuo, Ho‐Ming Su · 2021 · Journal of Personalized Medicine
72. Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
    Isabelle Johansson, Ilaria Dicembrini, Edoardo Mannucci, Francesco Cosentino · 2021 · EuroIntervention
73. Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes
    Dimitrios Chatzis, Konstantinos Kolokathis, Kalliopi Magounaki, Stefanos Chatzidakis, Konstantinos Avramidis, Marianna Leopoulou, Theodoros P. Angelopoulos, John Doupis · 2021 · touchREVIEWS in Endocrinology
74. Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia
    Phillip Lim, David Bleich · 2022 · International Journal of Cardiology Cardiovascular Risk and Prevention
75. Adiponectin Can Be an Early Predictable Marker for Type 2 Diabetes Mellitus and Nephropathy
    Veluri Ganesh, M Murugan, Siva Prasad Palem · 2022 · Cureus
76. Influence of hepatitis B virus on the prevalence of diabetes complications in patients with type 2 diabetes
    Xiyu Liu, Yan Zhou · 2022 · Journal of Diabetes Investigation
77. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
    Linong Ji, Xiaozhen Jiang, Qingshun Hao, Zhifeng Cheng, Kun Wang, Shuguang Pang, Mei‐Ying Liu, Yushan Guo, Xiaowen Chen, Xiuhai Su et al. · 2023 · Diabetes Obesity and Metabolism
78. Reducing Infection Rates with Enhanced Preoperative Diabetes Mellitus Diagnosis and Optimization Processes
    Sher‐Lu Pai, Daniela Andrea Haehn, Nancy E Pitruzzello, Sarika N. Rao, Shon Meek, Joan M Irizarry Alvarado · 2023 · Southern Medical Journal
79. Predictive Value of Noninvasive Peripheral Atherosclerosis Measurement for Coronary Artery Disease in Patients with Long T2DM Duration
    Wanjiao Chen, Li Wang, Bin Hu, Ying Zheng, Shuya Zhang, Zhong Zhou, Yifeng Mai · 2023 · Diabetes Metabolic Syndrome and Obesity
80. Control for multiple risk factors and incident heart failure and mortality in patients with diabetes mellitus: Insights from the Kailuan cohort study
    Wenqi Xu, Xinmu Li, Gary Tse, Jeffrey Shi Kai Chan, Shouling Wu, Tong Liu · 2024 · Current Problems in Cardiology
81. Successful Reimplementation Of A Very Low Carbohydrate Ketogenic Diet After SGLT2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis
    Ethan Fieger, Kristen Fadel, Amir H. Modarres, Edmond P. Wickham, Susan E. Wolver · 2020 · AACE Clinical Case Reports
82. Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome
    Jean Ferrières, Dominik Lautsch, Peter Bramlage, Martin Horack, Carl A. Baxter, Baishali M. Ambegaonkar, Peter Paul Toth, Kian Keong Poh, Gaetano Maria De Ferrari, Anselm Kai Gitt · 2020 · Archives of cardiovascular diseases
83. Association of Secreted Frizzled Related Protein 4 with Type 2 Diabetes Mellitus and its complications: A South Indian hospital based case control study
    Avivar Awasthi, Manjunath Hande, Pragna Rao, Thejesh Srinivas, Gagana Hanumaiah · 2020 · Clinical Epidemiology and Global Health
84. Coronary revascularization in patients with stable coronary disease and diabetes mellitus
    Salman Zahoor Bhat, Yan Yatsynovich, Umesh C. Sharma · 2021 · Diabetes and Vascular Disease Research
85. A Case-Control Study on Risk Factors affected Peripherals Neuropathic complication in Elderly with Type 2 Diabetes Mellitus
    Made Krisna Adi Jaya, Dewa Ayu Swastini, Baiq Leny Nopitasari, Putu Rika Veryanti · 2021 · Research Journal of Pharmacy and Technology
86. Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes
    Margaret F. Zupa, Ronald A. Codario, Kenneth J. Smith · 2021 · Journal of Comparative Effectiveness Research
87. Association of Epicardial Fat with Diastolic and Vascular Functions in Children with Type 1 Diabetes
    Faisal‐Alkhateeb Ahmad, Kotb Abbass Metwalley, Ismail Lotfy Mohamad · 2022 · Pediatric Cardiology
88. Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study
    Sérgio Alberto Cunha Vencio, André Gustavo Daher Vianna, Mariana Arruda Camara Ferreira da Silva, Dalton Bertolim Précoma · 2022 · Diabetology & Metabolic Syndrome
89. Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    Suzanne Meiring, Celine B.E. Busch, Annieke C.G. van Baar, Robert Hemke, Frits Holleman, Max Nieuwdorp, Jacques J.G.H.M. Bergman · 2022 · Cardiovascular Diabetology
90. Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
    Xiaoling Cai, Linong Ji · 2021 · Diabetes Therapy
91. Preclinical Evaluation of Baicalin for the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis
    Hengtong An, Luyao Liu, Tongtong He, Xiaohan Chen, Xiaofei Jin, Xiaohong Zhou, Weijuan Gao · 2025 · Planta Medica
92. Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the CAPTURE study
    Timothy M. E. Davis, Peter Grahame Colman, Charlotte Mary Hespe, Sarah Elizabeth Heywood, Michael C dʼEmden · 2022 · Internal Medicine Journal
93. Changes in lipid profile and glucose metabolism following administration of bupropion alone or in combination with naltrexone: A systematic review and meta‐regression analysis
    Yi Hu, Periyannan Velu, Pejman Rohani, Mohammad Hassan Sohouli · 2023 · European Journal of Clinical Investigation
94. EXpanding Technology-Enabled, Nurse-Delivered Chronic Disease Care (EXTEND): Protocol and Baseline Data for a Randomized Trial
    Jashalynn German, Qing Yang, Daniel Hatch, Allison A. Lewinski, Hayden Barry Bosworth, Brystana G. Kaufman, Ranee Chatterjee, Gina Pennington, Doreen Matters, Dong Hwan Lee et al. · 2024 · Contemporary Clinical Trials
95. A Retrospective Study of Brain-Heart Syndrome in Patients with Acute Cerebrovascular Diseases
    Hui Tang, Xiurong Xing, Yingna Han, Daiquan Gao, Piu Chan, Shengfang Zhang, Huixin Xue · 2024 · Risk Management and Healthcare Policy
96. Cardiovascular disease modifies the relationship between systolic blood pressure and outcomes in people with diabetes
    Anping Cai, Jiabin Wang, Xiaoxuan Feng, Gianfranco Parati, Ji-Guang Wang, Yingqing Feng, Zhiqiang Nie · 2024 · Diabetes Research and Clinical Practice
97. Efectividad y seguridad del tratamiento con iPCSK9 en vida real: experiencia de tres hospitales asturianos
    Raúl Rodríguez Escobedo, Silvia González Martínez, Lucía Díaz Naya, L. Suárez Gutiérrez, Juan Luís Fernández-Morera, María Riestra Fernández, Ceferino Martinez Faedo, Francisco Villazón González, Edelmiro Luis Menéndez Torre · 2021 · Medicina de Familia SEMERGEN
98. Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer?
    György Herczeg, Anikó Somogyi, Magdolna Herold, Ágnes Fodor, Klára Rosta, Magdolna Dank, Zsolt Láng, Zoltán Herold · 2022 · Open Medicine
99. Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease
    Xiaoying Li, Li Li, Sang Hoon Na, Francesca Santilli, Zhongwei Shi, Michael Joseph Blaha · 2022 · American Journal of Preventive Cardiology
100. Time, Technology, Social Support, and Cardiovascular Health of Emerging Adults With Type 1 Diabetes
     Margaret M. McCarthy, Joeyee Yan, Mary Christine Jared, Jeniece Trast Ilkowitz, MARY PAT GALLAGHER, Victoria Vaughan Dickson · 2023 · Nursing Research